Acquired immunodeficiency syndrome is a serious problem worldwide. Recent advances in the knowledge about human immunodeficiency virus (HIV) replication and the treatment of HIV infection have improved survival in HIV patients. Because of the longer survival in HIV patients, the more manifestations of late-stage HIV infection will be seen, including HIV-related cardiac diseases. The common cardiac manifestations in patients with the acquired immunodeficiency virus are pericardial effusion, myocarditis, dilated cardiomyopathy, endocarditis, pulmonary hypertension, malignant neoplasms, and drug-related cardiotoxicity. This review focuses on these cardiac manifestations in patients with the acquired immunodeficiency syndrome.
Acquired immunodeficiency syndrome (AIDS) is characterized by an acquired, profound, irreversible immunosuppression that predisposes the patient to multiple opportunistic infections, malignant neoplasms, and a progressive dysfunction of multiple organ systems. Cardiac involvement in AIDS patients was first described in 1983 by Autran et al,1 who reported myocardial Kaposi sarcoma at autopsy. The prevalence of cardiac involvement in AIDS patients has been reported to range between 28% and 73%.2 Recent advances in the knowledge about human immunodeficiency virus (HIV) replication and the treatment of HIV infection have improved survival in HIV patients.3-5 Because of the longer survival in HIV patients, the more manifestations of late-stage HIV infection will be seen, including HIV-related cardiac diseases. These cardiac diseases include pericardial effusion, myocarditis, dilated cardiomyopathy, endocarditis, pulmonary hypertension, malignant neoplasms, coronary artery disease, and drug-related cardiotoxicity.
Pericardial effusion is one of the most common forms of cardiovascular involvement in HIV infection. There are varieties of clinical manifestations, which include asymptomatic pericardial effusion, pericarditis, cardiac tamponade, and constrictive pericarditis. Approximately one fifth of AIDS patients have pericardial effusion.6-11 The pericardial effusion is often small and without hemodynamic consequence; however, large effusion can occur and may cause cardiac tamponade.12-14
The clinical manifestations of pericarditis are similar between patients with and without HIV infection.15 Moreno et al16 reviewed echocardiographic studies in 141 HIV-infected patients, and 55 (39.0%) of them had pericardial effusion. Most (34 of the 55) were small. The clinical presentation of pericarditis was compared between patients with small pericardial effusion and those with moderate to large pericardial effusion. They found that the presence of a pericardial friction rub and electrocardiographic repolarization abnormalities consistent with pericarditis were more often seen in patients with moderate to large pericardial effusions. The reason for these findings is unclear. Specific identifiable causes of pericardial effusion in AIDS patients are not always possible.17,18 The causative factors involved in the development of pericardial effusion have been described. Flum et al18 performed pericardial fluid cultures and pericardial biopsies in 29 AIDS patients with pericardial effusion who underwent a pericardial window procedure. The causes were identified in 7 (24%) of the 29 patients. The causes included Staphylococcus aureus (1 patient), Mycobacterium tuberculosis (1 patient), adenocarcinoma (2 patients), and lymphoma (3 patients). Staphylococcus aureus pericarditis is a serious condition, and cardiac tamponade may develop rapidly.19 Karve et al20 reported pneumococcal pericarditis in 2 HIV patients, and both of them developed cardiac tamponade. Sunderam et al21 studied a select group of 29 AIDS patients who had M tuberculosis. Of these 29 patients, 21 (72%) had extrapulmonary tuberculosis. Tuberculous pericarditis was found in 1 (5%) of these 21 patients with extrapulmonary tuberculosis. Zuger et al22 reported that 1 (4%) of 26 AIDS patients with cryptococcal infection had pericarditis. Eisenberg et al23 could identify the cause of pericardial effusion in 4 (29%) of 14 AIDS patients with pericardial effusion. The causes included lymphoma (1 patient), myocardial infarction (1 patient), and endocarditis (2 patients). Kaposi sarcoma has been reported to cause pericardial effusion and cardiac tamponade.24 Numerous case reports have shown multiple unusual organisms associated with pericardial effusion in HIV patients (Table 1).
Heidenreich et al14 studied the incidence of pericardial effusion and its relation to mortality in HIV patients. Two hundred thirty-one patients were recruited during a 5-year period, and 74 had AIDS. Fifteen patients with HIV infection had pericardial effusion, and 12 (80%) of these pericardial effusions were small. Only 2 patients (1 with a moderate and 1 with a large pericardial effusion) developed symptoms and signs of cardiac tamponade, which required drainage. Patients with AIDS who have pericardial effusion have a 9% annual incidence of cardiac tamponade, and 1% of all AIDS patients developed cardiac tamponade annually.14 The size of pericardial effusion did not correlate with the shortened survival, but the presence of pericardial effusion did. The mean ± SD 6-month survival was 36% ± 11% compared with 93% ± 3% in AIDS patients without effusion. The CD4 (T-helper lymphocyte) cell count was lower in AIDS patients with effusion than in those without effusion (0.059 vs 0.146 × 109/L).14 Pericardial effusion in HIV patients may be a marker of end-stage HIV infection because it is associated with low CD4 cell count and is often caused by opportunistic infections and malignant neoplasms seen in the advanced state of AIDS. Although pericardial effusion is seen in patients with the advanced stage of HIV infection, it rarely causes death in these patients.
Anderson et al37 suggested that myocarditis in HIV patients may play a role in the development of ventricular dysfunction. The autopsy incidence of myocarditis was approximately one third of all AIDS patients. A specific cause was found in less than 20% of these patients. Common pathogens in AIDS myocarditis include Toxoplasma gondii, M tuberculosis, and Cryptococcus neoformans. Other infectious organisms have been reported to include Myocobacterium avium-intracellulare complex, Aspergillus fumigatus, Candida albicans, Histoplasma capsulatum, Coccidioides immitis, cytomegalovirus, and herpes simplex.2 Recent data suggested that HIV alone can cause myocarditis. Either HIV or its proteins (p17, p24, and gp120/160) have been found in the heart specimens of patients with AIDS with or without cardiac diseases by culture, by in situ deoxyribonucleic acid hybridization, and by Southern blot tests.38-40
Superantigen plays an important role in the pathogenesis of many diseases by forming a trimolecular complex with major histocompatibility complex class II molecule on the antigen-presenting cells and the Vβ-specific region on the T-lymphocyte receptor. The binding results in a massive stimulation of the T lymphocyte. The role of superantigen in the pathogenesis of AIDS has been described.41 After the binding of HIV regulatory protein (Nef) with major histocompatibility complex class II on antigen-presenting cells, the T lymphocytes become activated. The activation of T lymphocytes stimulates the proliferation and release of cytokines such as interferon γ and interleukin 2. Therefore, the viral load in the heart will increase from creating a cellular reservoir for HIV. T-lymphocyte depletion may be caused by apoptosis, anergy, or both. Proliferation of the B cell may result in hypergammaglobulinemia. Autoimmune response may occur as a result of B-cell differentiation into immunoglobulin-secreting cells and activation of the T lymphocyte.41
Lymphocytic myocarditis was found in 37 (52%) of 71 patients who died of AIDS.37 There were 3 types of histological features: lymphocytic infiltrate with necrosis of the myocardial fibers, lymphocytic infiltrate without necrosis of the myocardial fibers,42 and focal and mild myocarditis with a mononuclear infiltrate.37 Reilly et al7 studied the relation between clinical and histopathological cardiac findings in patients with AIDS. Interestingly, myocarditis was found in all patients with congestive heart failure, left ventricle dysfunction, and ventricular tachycardia. Baroldi et al43 evaluated the relation between cardiac dysfunction and myocarditis. Of 26 patients with AIDS, 8 underwent premortem echocardiography. Of these 8 patients, 6 had abnormal cardiac function (abnormal fractional shortening, globular shape, hypokinesis, or mild ventricular dilation). All patients with abnormal echocardiographic findings had lymphocytic myocarditis with or without myocardial necrosis post mortem.
In 1986, Cohen et al44 described the first case of rapidly fatal, dilated cardiomyopathy in a patient with AIDS. The prevalence of dilated cardiomyopathy ranges from 10% to 30% by echocardiographic and autopsy studies.37,45,46 Several prospective clinical and echocardiographic studies have suggested that a subgroup of HIV-infected patients may be predisposed to the development of clinically significant and progressive heart disease. Herskowitz et al47 found that patients with severe symptomatic heart failure usually had a low CD4 cell count, myocarditis, and a persistent elevation of antiheart antibodies. The postmortem gross findings of dilated cardiomyopathy in patients with AIDS have included increased heart weight, with either biventricular or 4-chamber dilation, and a pale-appearing myocardium.48 Echocardiographic findings included 4-chamber enlargement, diffuse left ventricular hypokinesis, and decreased fractional shortening.45 Coudray and colleagues49 demonstrated that left ventricular diastolic impairment could occur in the early stage of HIV infection. Dilated cardiomyopathy occurs late in the course of HIV infection and is usually associated with a significantly reduced CD4 cell count47,50,51; however, there was no association between the progression of left ventricular dysfunction and the rate of CD4 cell count decline.52
The pathogenesis of cardiomyopathy remains unclear. Several studies35,44,53 have supported the direct role for HIV-1–mediated cardiac injury, but the mechanism remains unclear. One hypothesis focuses on the role of an alteration of T-helper cell function inducing myocardial inflammation by uncontrolled hypergammaglobulinemia.42 The HIV gene may provoke cell surface cardiac muscle protein, resulting in the induction of circulated cardiac autoantibodies, which can trigger a progressively destructive autoimmune reaction.54
Selenium deficiency and its association with cardiomyopathy have been described. Case reports55,56 of pediatric AIDS patients have shown an improvement of cardiac function after selenium supplementation. Barbaro et al57 performed a prospective, long-term clinical and echocardiographic follow-up study of 952 asymptomatic HIV-positive patients. An echocardiographic diagnosis of dilated cardiomyopathy was made in 76 patients (8.0%), with a mean annual incidence of 15.9 per 1000 patients during a mean ± SD follow-up period of 60.0 ± 5.3 months. All patients with an echocardiographic diagnosis of dilated cardiomyopathy underwent endomyocardial biopsy within 1 month. They found myocarditis in 63 (83%) of the patients with dilated cardiomyopathy on histological examination, and 36 (57%) of the patients with myocarditis had a positive hybridization signal for HIV nucleic acid sequences. Among these 36 patients who had myocarditis and a positive hybridization signal for HIV nucleic acid sequences, 6 (17%) were infected with Coxsackievirus group B, 2 (6%) were infected with cytomegalovirus, and 1 (3%) was infected with Epstein-Barr virus.
Marantic endocarditis or nonbacterial thrombotic endocarditis is characterized by friable, fibrinous clumps of platelets and red blood cells adherent to the cardiac valves without an inflammatory reaction. It is estimated that this condition occurs in 3% to 5% of AIDS patients.58 It usually occurs in patients older than 50 years. Marantic endocarditis is known to be associated with malignant neoplasms, hypercoagulable states, and chronic wasting disease.59-61 Mitral and aortic valves are commonly involved in HIV-negative patients,60 but the tricuspid valve is usually involved in AIDS patients.62 Systemic embolism can occur in up to 42% of patients, but most of these events are clinically silent. Embolization can involve the brain, lung, spleen, kidney, and coronary arteries.63 Systemic embolization from marantic endocarditis is a rare cause of death in AIDS patients.12
Infective endocarditis in patients with AIDS usually occurs in parenteral drug users. Human immunodeficiency virus infection may increase the risk of infective endocarditis among intravenous drug users.64 Nahass et al65 studied the causes of infective endocarditis in 34 HIV patients, and they found that S aureus (75%) and Streptococcus viridans (20%) were the major responsible organisms. Other unusual organisms described as case reports were Salmonella,66A fumigatus,67,68 and Pseudallescheria boydii.69 The tricuspid valve is the most commonly affected valve. The affected patients usually present with fever, sweats, weight loss, and coexisting pneumonia and/or meningitis.70 The presentation and survival of infective endocarditis in patients with and without HIV infection are generally not different; however, in the late stage of HIV-infected patients, significant increased mortality from infective endocarditis has been reported compared with asymptomatic HIV patients.65
Human immunodeficiency virus–associated pulmonary hypertension was first described by Kim and Factor in 1987.71 By 1998, 88 patients with HIV infection were described with this entity. The incidence of HIV-associated pulmonary hypertension is 1 in 200 compared with 1 in 200 000 in the general population.72 It is more common in male and young patients (mean age, 32 years). The common risk factors are intravenous drug use, homosexual contacts, and hemophilia. The major symptom of this condition is dyspnea.72 There was no correlation between either a history of opportunistic infections or CD4 cell count and the development of pulmonary hypertension.73 The mean pulmonary artery systolic pressure was 68 mm Hg. The major causes of death were right-sided heart failure and respiratory failure. Half of the patients died in 1 year.72 Petitpretz et al74 performed a prospective study of 20 patients with HIV infection and pulmonary hypertension and compared them with a group of 93 patients with primary pulmonary hypertension who were HIV negative. They found that patients with HIV infection were younger and had a lesser degree of disabilities. Interestingly, mortality between these 2 groups was not different. Plexogenic pulmonary arteriopathy was the most frequent pathologic finding.74
The pathogenesis of pulmonary hypertension associated with HIV infection is unclear. Mette et al75 were unable to demonstrate the presence of HIV in pulmonary endothelial cells by electron microscopy, immunochemistry, DNA in situ hybridization, and the polymerase chain reaction technique. This finding supports an indirect mechanism for HIV-associated pulmonary hypertension. Ehrenreich et al76 demonstrated that HIV-1 envelope glycoprotein (GP-120) stimulated the production of the secretion of endothelin 1 (a potent vasoconstrictor) and tumor necrosis factor α from macrophage. Human immunodeficiency virus–infected alveolar macrophage released tumor necrosis factor α and proteolytic enzymes. Lymphokine can enhance the adherence of the leukocyte to the endothelium and promote endothelial proliferation.72 Platelet-derived growth factor can stimulate smooth muscle cell and fibroblast proliferation and migration. Humbert et al77 showed that platelet-derived growth factor expression was increased in patients with HIV-associated pulmonary hypertension. Morse et al78 found that the incidence of HLA-DR6 and HLA-DR52 was increased in 10 HIV patients with primary pulmonary hypertension compared with matched control subjects. Human immunodeficiency virus–associated pulmonary hypertension is a diagnosis of exclusion. Other causes of pulmonary hypertension include talc granuloma, especially in intravenous drug abusers, portal hypertension, thromboembolism, and an airway disease.72
Two types of malignant neoplams affecting the heart have been described in patients with HIV infection: Kaposi sarcoma and malignant lymphoma.
In 1983, Autran et al1 first described Kaposi sarcoma of the heart in an HIV patient. The incidence of Kaposi sarcoma involving the heart ranged from 12% to 28% in retrospective autopsy findings.17,79 Most (90%) of the autopsies were performed on homosexual or bisexual patients.17 Cardiac involvement with Kaposi sarcoma in an HIV-infected patient usually occurs as a part of disseminated Kaposi sarcoma. Acquired immunodeficiency syndrome–related metastatic Kaposi sarcoma involves either the visceral layer of serous pericardium or the subepicardial fat. There is a predilection of Kaposi sarcoma to involve the subepicardial adipose tissue adjacent to a major coronary artery with or without involvement of the adventitia of the ascending aorta or pulmonary trunk.79 Pericardial and myocardial involvement have also been reported.59 Chyu et al80 demonstrated premortem detection of cardiac Kaposi sarcoma by transthoracic echocardiography, which revealed pericardial tamponade and a mobile multilobular mass at the apex protruding into the pericardial space. Clinical cardiac findings are obscure; most of the cases are found at autopsy. Fatal cardiac tamponade24,81 and pericardial constriction have been reported.2 Vijay et al82 reported 5 cases of Kaposi sarcoma of the visceral layer of serous pericardium or pericardium causing fatal tamponade in the patients with AIDS. Pericardicentesis was performed, resulting in a transient improvement in vital signs but with subsequent deterioration and death within a variable period ranging from 5 hours to a few days. The diagnosis of pericardial Kaposi sarcoma was delayed until autopsy. All were noted to have a tense pericardial sac with dark bloody fluid, presumably as a result of the pericardicentesis needle penetrating the Kaposi sarcoma lesions. Pericardicentesis not only has no diagnostic role but it is also a high-risk procedure in this group of patients. In patients with AIDS in whom the clinician has a high index of suspicion of Kaposi sarcoma pericardial effusion, a pericardial window should be the procedure of choice for providing decompression and establishing the pathologic diagnosis.
In 1985, the Centers for Disease Control and Prevention recognized the linkage between intermediate- and high-grade lymphoma and HIV seropositivity and included this in the diagnostic criteria for AIDS. Lymphoma is the second most common tumor that involves the heart. Cardiac involvement with non-Hodgkin lymphoma, usually derived from B cells, is typically high grade and is often disseminated early in patients with AIDS. Disseminated cardiac lymphoma is more common than primary cardiac lymphoma. It has been reported to account for 15% of all cardiac and pericardial metastases in non-AIDS series.83 Primary cardiac lymphoma is extremely rare.84 Patients may present with intractable congestive heart failure, pericardial effusion, cardiac arrhythmia,85-87 or cardiac tamponade.88 Patients usually have nonspecific symptoms, but rapid progression of cardiac dysfunction can occur after these symptoms. The most common gross appearance is nodular or polypoid masses predominantly involving the pericardium, with variable myocardial infiltration. Histologically, these are diffuse, aggressive lymphomas, usually of small noncleaved or immunoblastic types.85 Patients with mechanical obstruction may benefit from surgical resection.89 The prognosis of patients with HIV-associated cardiac lymphoma is generally poor, although clinical remission has been observed with combination chemotherapy.90
Coronary artery disease has been reported in a patient with HIV infection91,92 at autopsy. Eccentric atherosclerosis or fibrosis of the tunica media of the coronary artery was found at autopsy.91 Sclerohyalinosis of the smaller arteries and myocardial interstitial fibrosis lesions were also found.91 The cause of these lesions is uncertain. Coronary artery disease in HIV-positive patients may be due to atherogenesis as a result of virus-infected monocytes-macrophages, possibly through altered adhesion93 or due to angiitis.42,94 Atherosclerosis and atherothrombosis from dyslipoproteinemia caused by highly active antiretroviral therapy, especially protease inhibitors, have been reported.95,96
Drug-induced cardiotoxicity
Patients with HIV are exposed to many medications to treat conditions related to HIV diseases, such as cancer and opportunistic infections. Some of these medications may have cardiovascular toxicities. Dilated cardiomyopathy has been reported in a young male patient treated with amphotericin B.97 In this patient, cardiac function returned to normal after the medication had been discontinued for 6 months.97 Bradycardia was described in children treated with amphotericin B. The incidence was 6.7% in the patients who received amphotericin B and usually occurred between day 3 and day 7 after the start of therapy.98 Hypertension was found in 2 patients treated with amphotericin B, and the mechanism of this adverse effect was unclear.99 Doxorubicin cardiomyopathy has been well described and occurred with a total dose of 400 mg/m2 or more.100 The prevalence of hypertension associated with erythropoietin therapy is 47%, and the mechanism of this adverse effect may be related to an increase in hematocrit and blood viscosity.101 Reversible cardiomyopathy has been described in HIV patients treated with foscarnet sodium for cytomegalovirus esophagitis.102 Cohen et al103 described 2 patients who developed ventricular tachycardia during an intravenous infusion of ganciclovir. Sonnenblick and Rosin104 reviewed 44 cases of interferon-induced cardiotoxicity. Arrhythmia was the most common manifestation of cardiotoxicity (25 patients). Other cardiotoxicities included myocardial infarction or ischemia (9 patients), cardiomyopathy (5 patients), sudden death (2 patients), AV block (2 patients), and congestive heart failure (1 patient). Cardiac adverse effects from interferon were not associated with the dosage or the duration of treatment and were reversible in most patients.104 QT prolongation has been reported in patients treated with pentamidine,105,106 pyrimethamine,107 and the combination drug trimethoprim and sulfamethoxazole.108 Cardiac dysfunction has been found in adults or children treated with zidovudine. Zidovudine inhibits retroviral replication and interferes with the action of reverse transcriptase of HIV.109,110 Diffuse destruction of cardiac mitochondrial ultrastructures and inhibition of mitochondrial DNA replication may be responsible for zidovudine-induced cardiomyopathy (Table 2).111
Cardiac involvement is commonly seen in AIDS patients, and the pericardium, myocardium, and/or endocardium may be involved in these patients. Pericardial effusion is one of the most common types of cardiac involvement in HIV patients, and its mechanism is unclear but it may be related to infections or neoplasms. Myocarditis, the cause of which is usually difficult to identify, may be responsible for myocardial dysfunction. Opportunistic infections have been reported to be a cause of myocarditis, including the HIV itself. Dilated cardiomyopathy is usually found in the late stage of HIV infection, and myocarditis may be the triggering causative factor. Nonbacterial thrombotic endocarditis and infective endocarditis have been described in AIDS patients, both of which can cause significant morbidity in these patients. Human immunodeficiency virus–related pulmonary hypertension is a diagnosis of exclusion, and symptoms and signs may mimic other pulmonary conditions in AIDS patients. Cardiac Kaposi sarcoma and cardiac lymphoma are the frequently encountered malignant neoplasms in AIDS patients, and the prognosis is grave in patients with these conditions. Coronary artery disease has previously been documented and may be related to highly active antiretroviral therapy. Many cardiovascular adverse effects from medications used in HIV patients have been described. As the survival of HIV patients has improved mainly because of aggressive antiretroviral therapy, it is anticipated that more late complications from this fatal viral infection, including cardiac involvement, will be encountered. Early recognition and prompt treatment are important to prevent significant morbidity from cardiac involvement. Whether this approach will prolong survival in AIDS patients remains to be seen.
Accepted for publication May 27, 1999.
Reprints: Morris N. Kotler, MD, Division of Cardiovascular Diseases, Department of Medicine, Albert Einstein Medical Center, 5501 Old York Rd, Philadelphia, PA 19141 (e-mail: kotlerm@aehn2.einstein.edu).
1.Autran
BGorin
ILeibowitch
M
et al. AIDS in a Haitian woman with cardiac Kaposi's sarcoma and Whipple's disease.
Lancet. 1983;1767- 768
Google ScholarCrossref 2.Kaul
SFishbein
MCSiegel
RJ Cardiac manifestations of acquired immune deficiency syndrome.
Am Heart J. 1991;122535- 544
Google ScholarCrossref 3.Enger
CGraham
NPeng
Y
et al. Survival from early, intermediate, and late stages of HIV infection.
JAMA. 1996;2751329- 1334
Google ScholarCrossref 4.Monsuez
JJVittecoq
DKinney
EL Increased survival of AIDS patients with heart disease within 10 years?
Circulation. 1996;942312- 2313
Google Scholar 5.Mocroft
AYoule
MMorcinek
J
et al. Survival after diagnosis of AIDS: a prospective observational study of 2625 patients.
BMJ. 1997;314409- 413
Google ScholarCrossref 6.Fink
LReichek
NSutton
MG Cardiac abnormalities in acquired immune deficiency syndrome.
Am J Cardiol. 1984;541161- 1163
Google ScholarCrossref 7.Reilly
JMCunnion
REAnderson
DW Frequency of myocarditis, left ventricular dysfunction and ventricular tachycardia in the acquired immunodeficiency syndrome.
Am J Cardiol. 1988;62789- 793
Google ScholarCrossref 8.Hecht
SRBerger
MVanTosh
ACroxson
S Unsuspected cardiac abnormalities in the acquired immune deficiency syndrome: an echocardiographic study.
Chest. 1989;96805- 808
Google ScholarCrossref 9.Corallo
SMutinelli
MMoroni
M
et al. Echocardiography detects myocardial damage in AIDS: prospective study in 102 patients.
Eur Heart J. 1988;9887- 892
Google Scholar 10.Monsuez
JJKinney
ELVittecoq
D
et al. Comparison among acquired immune deficiency syndrome patients with and without clinical evidence of cardiac disease.
Am J Cardiol. 1988;621311- 1313
Google ScholarCrossref 11.Strang
JIKakaza
HHGibson
DGGirling
DJNunn
AJFox
W Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei.
Lancet. 1987;21418- 1422
Google ScholarCrossref 12.Anderson
DWVirmani
R Emerging patterns of heart disease in human immunodeficiency virus infection.
Hum Pathol. 1990;21253- 259
Google ScholarCrossref 13.Thuesen
LMoller
A Heart involvement in HIV infection.
Nord Med. 1994;109298- 299
Google Scholar 14.Heidenreich
PAEisenberg
MJKee
LL
et al. Pericardial effusions in AIDS: incidence and survival.
Circulation. 1995;923229- 3234
Google ScholarCrossref 15.Malu
KLongo-Mbenza
BLurhuma
ZOdio
W Pericarditis and acquired immunodeficiency syndrome [in French].
Arch Mal Coeur Vaiss. 1988;81207- 211
Google Scholar 16.Moreno
RVillacastin
JPBueno
H
et al. Clinical and echocardiographic findings in HIV patients with pericardial effusion.
Cardiology. 1997;88397- 400
Google ScholarCrossref 19.Decker
CFTuazon
CU
Staphylococcus aureus pericarditis in HIV-infected patients.
Chest. 1994;105615- 616
Google ScholarCrossref 20.Karve
MMMurali
MRShah
HMPhelps
KR Rapid evolution of cardiac tamponade due to bacterial pericarditis in two patients with HIV-1 infection.
Chest. 1992;1011461- 1463
Google ScholarCrossref 21.Sunderam
GMcDonald
RJManiatis
TOleske
JKapila
RReichman
LB Tuberculosis as a manifestation of the acquired immunodeficiency syndrome (AIDS).
JAMA. 1986;256362- 366
Google ScholarCrossref 22.Zuger
ALouie
EHolzman
RSSimberkoff
MSRahal
JJ Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment.
Ann Intern Med. 1986;104234- 240
Google ScholarCrossref 24.Stotka
JLGood
CBDowner
WRKapoor
WN Pericardial effusion and tamponade due to Kaposi's sarcoma in acquired immunodeficiency syndrome.
Chest. 1989;951359- 1361
Google ScholarCrossref 25.Holtz
HALavery
DPKapila
R Actinomycetales infection in the acquired immunodeficiency syndrome.
Ann Intern Med. 1985;102203- 205
Google ScholarCrossref 26.Ferguson
RYee
SFinkle
HRose
TSchneider
VGee
G
Listeria-associated pericarditis in an AIDS patient.
J Natl Med Assoc. 1993;85225- 228
Google Scholar 27.Lee-Chiong
TSadigh
MSimms
MBuller
G Case reports: pericarditis and lymphadenitis due to
Rhodococcus equi.
Am J Med Sci. 1995;31031- 33
Google ScholarCrossref 28.Legras
ALemmens
BDequin
PFCattier
BBesnier
JM Tamponade due to
Rhodococcus equi in acquired immunodeficiency syndrome.
Chest. 1994;1061278- 1279
Google ScholarCrossref 29.Kroon
Fvan't Wout
JWWeiland
HTvan Furth
R
Chlamydia trachomatis pneumonia in an HIV-seropositive patient.
N Engl J Med. 1989;320806- 807
Google ScholarCrossref 30.Woods
GLGoldsmith
JC Fatal pericarditis due to
Mycobacterium avium intracellulare in acquired immunodeficiency syndrome.
Chest. 1989;951355- 1357
Google ScholarCrossref 31.Choo
PSMcCormack
JG
Mycobacterium avium: a potentially treatable cause of pericardial effusions.
J Infect. 1995;3055- 58
Google ScholarCrossref 32.Moreno
FSharkey-Mathis
PKMokulis
ESmith
JA
Mycobacterium kansasii pericarditis in patients with AIDS.
Clin Infect Dis. 1994;19967- 969
Google ScholarCrossref 33.Zakowski
MFIanuale-Shanerman
A Cytology of pericardial effusions: AIDS patients.
Diagn Cytopathol. 1993;9266- 269
Google ScholarCrossref 34.Guerot
EAissa
FKayal
S
et al.
Toxoplasma pericarditis in acquired immunodeficiency syndrome.
Intensive Care Med. 1995;21229- 230
Google ScholarCrossref 35.Nathan
PEArsura
ELZappi
M Pericarditis with tamponade due to cytomegalovirus in the acquired immunodeficiency syndrome.
Chest. 1991;99765- 766
Google ScholarCrossref 36.Freedberg
RSGindea
AJDieterich
DTGreene
JB Herpes simplex type 2 pericarditis and bilateral facial palsy in a patient with AIDS.
N Y State J Med. 1987;87304- 306
Google Scholar 37.Anderson
DWVirmani
RReilly
JM
et al. Prevalent myocarditis at necropsy in acquired immunodeficiency syndrome.
J Am Coll Cardiol. 1988;11792- 799
Google ScholarCrossref 38.Calabrese
LHProffitt
MRYen-Lieberman
BHobbs
RERatliff
NB Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium.
Ann Intern Med. 1987;107691- 692
Google ScholarCrossref 40.Grody
WWCheng
LLewis
W Infection of the heart by the human immunodeficiency virus.
Am J Cardiol. 1990;66203- 206
Google ScholarCrossref 41.Johnson
HMTorres
BASoos
JM Superantigens: structure and relevance to human disease.
Proc Soc Exp Biol Med. 1996;21299- 109
Google ScholarCrossref 42.Acierno
LJ Cardiac complications in acquired immunodeficiency syndrome (AIDS): a review.
J Am Coll Cardiol. 1989;131144- 1154
Google ScholarCrossref 43.Baroldi
GCorallo
SMoroni
M
et al. Focal lymphocytic myocarditis in acquired immunodeficiency syndrome (AIDS): a correlative morphologic and clinical study in 26 consecutive fatal cases.
J Am Coll Cardiol. 1988;12463- 469
Google ScholarCrossref 44.Cohen
ISAnderson
DWVermani
R
et al. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome.
N Engl J Med. 1986;315628- 630
Google ScholarCrossref 45.Himelman
RBChung
WSChernoff
DNSchiller
NBHollander
H Cardiac manifestations of human immunodeficiency virus infection: a two-dimensional echocardiographic study.
J Am Coll Cardiol. 1989;131030- 1036
Google ScholarCrossref 46.Levy
WSSimon
GLRios
JCRoss
AM Prevalence of cardiac abnormalities in human immunodeficiency virus infection.
Am J Cardiol. 1989;6386- 89
Google ScholarCrossref 47.Herskowitz
AWilloughby
SBVlahov
KBaughman
KLAnsari
AA Dilated heart muscle disease associated with HIV infection.
Eur Heart J. 1995;16(suppl O)50- 55
Google ScholarCrossref 48.Roldan
EOMoskowitz
LHensley
GT Pathology of the heart in acquired immunodeficiency syndrome.
Arch Pathol Lab Med. 1987;111943- 946
Google Scholar 49.Coudray
Nde Zuttere
DForce
D
et al. Left ventricular diastolic function in asymptomatic and symptomatic human immunodeficiency virus carriers: an echocardiographic study.
Eur Heart J. 1995;1661- 67
Google ScholarCrossref 50.Currie
PFJacob
AJForeman
ARElton
RABrettle
RPBoon
NA Heart muscle disease related to HIV infection: prognostic implications.
BMJ. 1994;3091605- 1607
Google ScholarCrossref 51.Jacob
AJSutherland
GRBird
AG
et al. Myocardial dysfunction in patients infected with HIV: prevalence and risk factors.
Br Heart J. 1992;68549- 553
Google ScholarCrossref 52.Lipshultz
SEEasley
KAOrav
EJ
et al. Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study.
Circulation. 1998;971246- 1256
Google ScholarCrossref 53.Ho
DDPomerantz
RJKaplan
JC Pathogenesis of infection with human immunodeficiency virus.
N Engl J Med. 1987;317278- 286
Google ScholarCrossref 54.Herskowitz
ANeumann
DAAnsari
AA Concepts of autoimmunity applied to idiopathic dilated cardiomyopathy.
J Am Coll Cardiol. 1993;221385- 1388
Google ScholarCrossref 55.Dworkin
BMAntonecchia
PPSmith
F
et al. Reduced cardiac selenium content in AIDS.
JPEN J Parenter Enteral Nutr. 1989;13644- 647
Google ScholarCrossref 56.Kavanaugh-McHugh
ALRuff
ALPerlman
EHutlon
NModlin
JRowe
S Selenium deficiency and cardiomyopathy in acquired immunodeficiency syndrome.
JPEN J Parenter Enteral Nutr. 1991;15347- 349
Google ScholarCrossref 57.Barbaro
GDi Lorenzo
GGrisorio
BBarbarini
G Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients.
N Engl J Med. 1998;3391093- 1099
Google ScholarCrossref 58.Currie
PFSutherland
GRJacob
AJBell
JEBrettle
RPBoon
NA A review of endocarditis in acquired immunodeficiency syndrome and human immunodeficiency virus infection.
Eur Heart J. 1995;16(suppl B)15- 18
Google ScholarCrossref 59.Cammarosano
CLewis
W Cardiac lesion in acquired immune deficiency syndrome (AIDS).
J Am Coll Cardiol. 1985;5703- 706
Google ScholarCrossref 60.Lopez
JARoss
RSFishbein
MCSeigel
RJ Nonbacterial thrombotic endocarditis.
Am Heart J. 1987;113773- 784
Google ScholarCrossref 61.Rosen
PArmstrong
O Nonbacterial thrombotic endocarditis in patients with malignant neoplastic disease.
Am J Med. 1973;5423- 29
Google ScholarCrossref 62.Anderson
DWVirmani
R Cardiac pathology of HIV disease. Joshi
VVed.
Pathology of AIDS and Other Manifestations of HIV Infection. New York, NY Igaku-Shoin Medical Publishers1992;165- 185
Google Scholar 64.Manoff
SBVlahov
DHerskowitz
A
et al. Human immunodeficiency virus infection and infective endocarditis among injecting drug users.
Epidemiology. 1996;7566- 570
Google ScholarCrossref 65.Nahass
RGWeinstein
MPBartels
JGocke
DJ Infective endocarditis in intravenous drug users: a comparison of human immunodeficiency virus type 1–negative and –positive patients.
J Infect Dis. 1990;162967- 970
Google ScholarCrossref 66.Bestetti
RBFigueiredo
JFDa Costa
JC
Salmonella tricuspid endocarditis in an intravenous drug abuser with human immunodeficiency virus infection.
Int J Cardiol. 1991;30361- 362
Google ScholarCrossref 67.Henochowicz
SMustafa
MLawrinson
WEPistole
MLindsay
J
Jr Cardiac aspergillosis in acquired immune deficiency syndrome.
Am J Cardiol. 1985;551239- 1240
Google ScholarCrossref 68.Cox
JNdi
Dio FPizzolato
GPLerch
RPochon
N
Aspergillus endocarditis and myocarditis in a patient with the acquired immunodeficiency syndrome (AIDS): a review of the literature.
Virchows Arch. 1990;417255- 259
Google ScholarCrossref 69.Raffanti
SPFyfe
BCarreiro
SSharp
SEHyma
BARatzan
KR Native valve endocarditis due to
Pseudallescheria boydii in a patient with AIDS: case report and review.
Rev Infect Dis. 1990;12993- 996
Google ScholarCrossref 70.Rivera Del Rio
JRFlores
RMelendez
JGomez
MAVila
SHunter
R Profile of HIV patients with and without bacterial endocarditis.
Cell Mol Biol (Noisy-le-grand). 1997;431153- 1160
Google Scholar 71.Kim
KKFactor
SM Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome.
Hum Pathol. 1987;181293- 1296
Google ScholarCrossref 72.Mesa
RAEdell
ESDunn
WFEdwards
WD Human immunodeficiency virus infection and pulmonary hypertension.
Mayo Clin Proc. 1998;7337- 44
Google ScholarCrossref 74.Petitpretz
PBrenot
FAzarian
R
et al. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension.
Circulation. 1994;892722- 2727
Google ScholarCrossref 75.Mette
SAPalevsky
HIPietra
GG
et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection: a possible viral etiology for some forms of hypertensive pulmonary arteriopathy.
Am Rev Respir Dis. 1992;1451196- 1200
Google ScholarCrossref 76.Ehrenreich
HRieckmann
PSinowatz
F
et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120.
J Immunol. 1993;1504601- 4609
Google Scholar 77.Humbert
MMonti
GFartoukh
M
et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients.
Eur Respir J. 1998;11554- 559
Google Scholar 78.Morse
JHBarst
RJItescu
S
et al. Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles.
Am J Respir Crit Care Med. 1996;1531299- 1301
Google ScholarCrossref 79.Silver
MAMacher
AMReichert
CM
et al. Cardiac involvement by Kaposi's sarcoma in acquired immune deficiency syndrome.
Am J Cardiol. 1984;53983- 985
Google ScholarCrossref 80.Chyu
KYBirnbaum
YNaqvi
TFishbeim
MCSeigal
RJ Echocardiographic detection of Kaposi's sarcoma causing cardiac tamponade in a patient with acquired immunodeficiency syndrome.
Clin Cardiol. 1998;21131- 133
Google ScholarCrossref 81.Steigman
CKAnderson
DWMaher
AMSennesh
JDVirmani
R Fatal cardiac tamponade in AIDS with epicardial Kaposi's sarcoma.
Am Heart J. 1989;1161105- 1107
Google ScholarCrossref 82.Vijay
VAloor
RKYalla
SM
et al. Pericardial tamponade from Kaposi's sarcoma: role of early pericardial window.
Am Heart J. 1996;132897- 899
Google ScholarCrossref 83.Peterson
CDRobinson
QAKurnich
JE Involvement of the heart and pericardium in the malignant lymphoma [letter].
Am J Med Sci. 1976;272161
Google ScholarCrossref 85.Holladay
AOSiegel
RJSchwartz
DA Cardiac malignant lymphoma in acquired immune deficiency syndrome.
Cancer. 1992;702203- 2207
Google ScholarCrossref 86.Goldfarb
AKing
CLRosenzweig
BP
et al. Cardiac lymphoma in the acquired immunodeficiency syndrome.
Am Heart J. 1989;1181340- 1344
Google ScholarCrossref 87.Constantino
AWest
TEGupta
MLoghmanee
F Primary cardiac lymphoma in a patient with acquired immune deficiency syndrome.
Cancer. 1987;602801- 2805
Google ScholarCrossref 88.Aboulafia
DMBush
RPicozzi
VJ Cardiac tamponade due to primary pericardial lymphoma in a patient with AIDS.
Chest. 1994;1061295- 1299
Google ScholarCrossref 89.Horowitz
MDCox
MMNeibart
RMBlaker
AMInterian
A
Jr Resection of right atrial lymphoma in a patient with AIDS.
Int J Cardiol. 1992;34139- 142
Google ScholarCrossref 90.Duong
MDubois
CBuisson
M
et al. Non-Hodgkin's lymphoma of the heart in patients infected with human immunodeficiency virus.
Clin Cardiol. 1997;20497- 502
Google ScholarCrossref 91.Paton
PTabib
ALoire
RTete
R Coronary artery lesions and human immunodeficiency virus infection.
Res Virol. 1993;144225- 231
Google ScholarCrossref 92.Tabib
AGreenland
TMercier
ILoire
RMornex
JF Coronary lesions in young HIV-positive subjects at necropsy [letter].
Lancet. 1992;340730
Google ScholarCrossref 93.Meltzer
MSSkillman
DRHoover
DL
et al. Macrophages and the human immunodeficiency virus.
Immunol Today. 1990;11217- 223
Google ScholarCrossref 94.Kestelyn
PLepage
PVan de Perre
P
et al. Perivasculitis of retinal vessels as an important sign in children with AIDS-related complex.
Am J Ophthalmol. 1985;100614- 615
Google Scholar 95.Henry
KMelroe
HHuebsch
J
et al. Severe premature coronary artery disease with protease inhibitors [letter].
Lancet. 1998;3511328
Google ScholarCrossref 96.Behrens
GSchmidt
HMeyer
DStoll
MSchmidt
RE Vascular complications associated with use of HIV protease inhibitors [letter].
Lancet. 1998;3511958
Google ScholarCrossref 97.Arsura
ELIsmail
YFreeman
SKarunakav
AR Amphotericin B–induced dilated cardiomyopathy.
Am J Med. 1994;97560- 562
Google ScholarCrossref 98.Levy
MDomaratzki
JKoren
G Amphotericin-induced heart rate decrease in children.
Clin Pediatr (Phila). 1995;34358- 364
Google ScholarCrossref 99.Le
YRana
KZDudley
MN Amphotericin B–associated hypertension.
Ann Pharmacother. 1996;30765- 767
Google Scholar 100.Bristow
MRMason
JWBillingham
MEDaniels
JR Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization.
Ann Intern Med. 1978;88168- 175
Google ScholarCrossref 101.Raine
AE Hypertension, blood viscosity and cardiovascular morbidity in renal failure: implications of erythropoietin therapy.
Lancet. 1988;197- 100
Google ScholarCrossref 102.Brown
DLSather
SCheitlin
MD Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient.
Am Heart J. 1993;1251439- 1441
Google ScholarCrossref 103.Cohen
AJWeiser
BAfzal
QFuhrer
J Ventricular tachycardia in two patients with AIDS receiving ganciclovir (DHPG).
AIDS. 1990;4807- 809
Google ScholarCrossref 105.Girgis
IGualberti
JLangan
L
et al. A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients.
Chest. 1997;112646- 653
Google ScholarCrossref 106.Stein
KMHaronian
HMensah
GAAcosta
AJacobs
JKligfield
P Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of
Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
Am J Cardiol. 1990;66888- 889
Google ScholarCrossref 107.von Seidlein
LJaffar
SGreenwood
B Prolongation of QTc interval in African children treated for falciparum malaria.
Am J Trop Med Hyg. 1997;56494- 497
Google Scholar 108.Lopez
JAHarold
JGRosenthal
MCOseran
DSSchapira
JNPeter
T QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole.
Am J Cardiol. 1987;59376- 377
Google ScholarCrossref 109.Domanski
MJSloas
MMFollmann
DA
et al. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus.
J Pediatr. 1995;127137- 146
Google ScholarCrossref 110.Herskowitz
AWilloughby
SBBaughman
KLSchlman
SPBartlett
JD Cardiomyopathy associated with anti-retroviral therapy in patients with human immunodeficiency virus infection: a report of six cases.
Ann Intern Med. 1992;116311- 313
Google ScholarCrossref 111.Lewis
WSimpson
JFMeyer
RR Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine.
Circ Res. 1994;74344- 348
Google ScholarCrossref